Background: The association between renin C-4063T and angiotensinogen (AGT) T174M, M235T, and A-6G polymorphisms with diabetic nephropathy (DN) was investigated in Tunisian type 2 diabetes (T2DM) patients. Methods: Study subjects comprised 917 T2DM patients (405 normoalbuminuric, 329 microalbuminuric and 185 macroalbuminuric). Genotyping was done by PCR-RFLP.
Introduction
Diabetic nephropathy (DN) is a leading cause of morbidity and mortality in type 2 diabetes (T2DM) patients, 1, 2 and is multifactorial, with both modifiable (hypertension, smoking, hyperlipidaemia) and non-modifiable (race, genetic background) factors influencing its susceptibility. 3, 4 DN is characterised by progressive deterioration of renal function and hypertension, and is aggravated by hyperglycemia. 5, 6 The progression of DN is controlled by adequate glycaemic control, and effective hypertension management, together with blockade of the renin-angiotensin-aldosterone system (RAAS), 2, 7 principally by angiotensin converting enzyme inhibitor (ACE-I) and angiotensin II type 1 receptor blocker (ARB). 2, 8, 9 RAAS is an endocrine system responsible for systemic regulation of sodium homeostasis, extracellular fluid volume, vascular tone and blood pressure. 10, 11 The effects of RAAS are predominantly mediated by angiotensin II (ANG II), which is produced by the cleavage of angiotensin I (AGT I) by ACE, and to a lesser extent by chymase; AGT itself being synthesised by the cleavage of the precursor angiotensinogen by renin. 12, 13 ANG II binds angiotensin type 1 (AT1) and angiotensin type 2 (AT2) receptors once liberated; the former being responsible for ANG II hemodynamic (vasoconstriction) and renal (sodium and fluid retention) effects. [11] [12] [13] Activation of AT1 receptors also stimulates ANG II-induced release of aldosterone from the adrenal cortex. On the other hand, ANG II stimulation of AT2 receptor antagonises AT1 receptor-induced effects. 13, 14 Increasing body of evidence implicates RAAS in DN pathogenesis. 8, 15, 16 This was based on the findings that ANG II induces progressive renal injury in DN, in part by increasing cellular growth and proliferation and matrix synthesis, leading to glomerular sclerosis. 17 Blockade of RAAS by ACE-I and ARBs prevented structural and functional changes in the diabetic kidney, further establishing a role for RAAS in DN. 2, 18 Several studies investigated the possible associations between RAAS gene polymorphisms, including renin (C-4063T) and angiotensinogen (AGT; T174M, M235T and A-6G) and DN susceptibility, with inconsistencies. M235T variant associated with higher levels of circulating AGT, 19, 20 was associated with hypertension 21, 22 and faster progression to end-stage renal disease (ESRD) in glomerulonephritis patients, 23 and increased susceptibility to nephropathy in type 1 diabetes (T1D) patients; 24 others failed to establish a role for this variant in DN. [25] [26] [27] In addition, A-6G promoter variant increases the rate of AGT gene transcription, and was reported to be associated with hypertension by some, 28 but not all 27 studies. Here, we investigate whether these four common polymorphisms of the RAAS: renin C-4063T and AGT (T174M, M235T and A-6G) affect the increased risk of nephropathy in T2DM patients.
Methods

Subjects
A total of 917 consecutive unrelated adult Tunisian T2DM patients of Arab origin (Berbers excluded) were recruited from the outpatient diabetes clinics of Farhat Hached University Hospital (Sousse) and Fattouma Bourguiba University Hospital (Monastir, Tunisia). Demographic details were recorded for all participants, which included age, gender, ethnic origin, BMI, age at onset and duration of diabetes, first-degree diabetes family history, history of chronic diabetes complications and other systemic illness, and treatment of diabetes, including date of initiation and/ or discontinuation of oral agents or insulin.
T2DM diagnosis was based on clinical and laboratory features as per the 1999 WHO criteria for diabetes classification and diagnosis (WHO reference); none of the patients ever had ketoacidosis. T2DM treatment included diet (15.4%) and/or oral anti-diabetic drugs (sulphonureas, biguanides, glitazones; 84.4%), and/or insulin (15.3%); all subjects who required insulin were treated with oral drugs for at least two years. T2DM medications were given as mono-(32.2%), double-(46.2%), or triple-(6.0%) agents. T2DM subjects who agreed to participate in the study were asked to sign an informed consent form, and the study was carried out in accordance with the Helsinki Declaration of 1975 guidelines, and was approved by the University of Monastir institutional review board; signed informed consent was obtained from all subjects.
Assessment of diabetic nephropathy
Participants underwent fasting venous sampling for glucose, HbA1c, serum urea and creatinine, and lipid profile (HDLcholesterol, LDL-cholesterol, total cholesterol and triglycerides). Morning urine samples were tested for proteinuria by protein dipsticks (Combur test; Roche Diagnostic, Mannheim, Germany); negative cases were re-tested for albuminuria (albumin:creatinine ratio), whereas positive cases were retested for total protein (protein:creatinine ratio). Glomerular filtration rate (GFR) was calculated using the Modification of Diet in Renal Disease Study equation (MDRD). 29 Diabetic nephropathy (DN) was based on the 24-hour urinary albumin excretion rate (AER), and was positive according to persistent microalbuminuria without frank proteinuria, persistent proteinuria (overt nephropathy), persistent renal impairment (plasma creatinine > 140 umol/L), with microalbuminuria or proteinuria.
Normoalbuminuria (n = 405) was defined as AER values persistently <30 mg/24 hour, microalbuminuria (n = 329) was defined as AER values 30-300 mg/24 hour, and macroalbuminuria (n = 183) was positive with persistent AER of > 300 mg/24 hour, on at least two of three collections done in a 3-6 month period. 29 Hypertension assessment was as per the joint national criteria for hypertension classification (JNVII), following two or more seated blood pressure readings, and the use of antihypertensive medication (ACE-I, ARBs, β blockers, diuretics and calcium antagonists), which were administered as mono-(26.1%), double-(11.0%), triple-(3.4%) or quadruple-(1.0%) drug regimens. Hyperlipidaemia was defined according to elevated total cholesterol (> 5.2 mmol/L), triglycerides (> 1.8 mmol/L) or both, and/or if the patient was on lipid-lowering medication. Overweight was defined as BMI 25-30 kg/ m 2 , obesity as BMI ≥ 30 kg/m 2 and normal waist-to-hip ratio was defined at < 0.90 (males) and < 0.85 (females).
Assessment of diabetic retinopathy
All patients were subjected to ophthalmological examination, which included corrected visual acuity, funduscopic examination and photography, and slitlamp microscopic examination with and without preset lens. Diabetic retinopathy (DR) was determined and graded by an ophthalmologist, and was defined as at least one microaneurysm or haemorrhage or exudate in either eye. Fluorescein angiography was performed on some patients to confirm the funduscopic findings.
Biochemical analysis
Serum glucose was measured in a fluoride oxalate tube by the hexokinase method (Cobas Integra 800; Roche, Mannheim, Germany), and total haemoglobin and HbA1c levels were obtained after hemolysing EDTA anti-coagulated blood by colourimetric and immuno-turbidimetric methods, respectively, on COBAS Integra 800; Hb to HbA1c yielded percent HbA1c levels. Serum lipids (total cholesterol, HDL and LDL and triglycerides) were quantitated by an enzymatic colourimetric method (Integra 800; Roche), and serum creatinine was assayed by the Jaffe reaction method (Integra 800). Additional testing for liver-function tests, renalfunction tests and serum electrolytes was done on a Dade Boehring instrument.
RAAS genotyping. AGT A-6G genotyping was assessed by
Bst NI digestion of the 308 bp PCR product using the following primers: (sense) 5′-CCC TCA GCT ATA AAT AGA GCA TC-3′, and (antisense): 5′-GCA GGA AGA CCT GAC CAT CT-3′; with the G allele seen as 245 and 63 bp fragments, whereas the A allele was visualised as 209, 63 and 36 bp fragments. AGT T174M polymorphism was assessed by Nco I digestion of the 674 bp PCR product using the following primers: (sense) 5′-CAA TTC AGG CCA AGA CAT CC-3′, and (antisense): 5′-GCC AGA GCC AGC AGA GAG-3′; with the C allele seen as 502 and 172 bp bands, and the T allele visualised as 256, 246 and 172 bp fragments. AGT M235T genotyping was determined by BstUI digestion of the 302 bp PCR product using the following primers: (sense) 5′-GAT GCG CAC AAG GTC CTG-3′, and (antisense): 5′-CAGGGT GCTGTCCACACTGGCTCGC-3′; with the T allele seen as 302 bp and the C allele seen as 278 and 24 bp fragments. Renin C-4063T polymorphism was determined by Taq I digestion of the 235 bp PCR product using the following primers: (sense) 5′-AAA CTA GAA TGG GCT ACC AGA-3′, and (antisense): 5′-GCT GTG ACT TGT CTC TTC CTG A-3′; with the C (163 and 68 bp) and T (235 bp) alleles visualised on 2.5% agarose gel. A number of samples (n = 100) selected at random were independently and blindly genotyped twice with concordant results.
Statistical analysis
Statistical analysis was performed on SPSS v. 17.0 software (SPSS, Chicago, Illinois, USA). Data were expressed as mean ± SD (continuous variables), or as percentages of total (categorical variables). The overall power (83.9%) was calculated as the average power over the SNPs genotyped (Genetic Power Calculator; SGDP Statistical Genetics Group), which related to an estimated odds ratio of 1.24. Pearson c 2 or Fisher's exact tests were used to assess intergroup significance, and Student's t-test was used to determine differences in means. Allele frequencies were calculated by the gene-counting method, and each polymorphism was tested for Hardy-Weinberg equilibrium using c 2 goodness-of-fit test (HPlus 2.5).
AGT haplotype estimation was done by the expectation maximisation method, where the sum of probability estimates for all possible haplotypes equals 1.0. Where haplotype assignment was uncertain (heterozygous carriers), the haplotype assignment probability estimate was used to determine the individual's contribution to that haplotype. AGT haplotypes were coded as per the allele at each locus; the first letter refers to A-6G, the second to the T174M and the third to M235T alleles. The contribution of confounding variables was assessed by forward logistic regression model; significant factors in c 2 test were analysed in multivariate logistic regression; results being expressed as p value, odds ratio (OR) and 95% confidence intervals (CI).
Results
Study subjects
The characteristics of study participants are shown in table 1. The three patient groups were matched for gender, age, BMI, waist-to-hip ratio, prevalence of hypertension, and age at disease onset. Longer disease duration was seen in microalbuminuric and macroalbuminuric patients compared to normoalbuminuric patients, with macroalbuminuric patients having lower disease duration than microalbuminuric patients (p < 0.05). Compared to normoalbuminuric patients, higher HbA1c, serum urea and creatinine, and higher AER were seen in microalbuminuric and macroalbuminuric patients, together with higher total cholesterol. DR was more pronounced in microalbuminuric (73.2%) and macroalbuminuric (86.3%) patients than in normoalbuminuric patients (13.5%). Family history of diabetes, and the prevalence of coronary heart disease (CHD) and dyslipidaemia were comparable between the three patient groups (data not shown).
Genotype analysis
The frequencies of (mutant) AGT 235T (p < 0.001) and AGT -6G (p < 0.001) alleles were higher in DN patients than in normoalbuminuric T2DM controls (table 2). The frequency of AGT 235T/T genotype was higher in microalbuminuric (22.2%) and macroalbuminuric (18.0%), compared to normoalbuminuric (4.9%) patients (p < 0.001). Higher frequency of AGT -6G/G genotype was seen in microalbuminuric and macroalbuminuric, compared to normoalbuminuric patients (p < 0.001). The allele and genotype distribution of AGT T174M and renin C-4063T SNPs were comparable between microalbuminuric and macroalbuminuric DN cases and T2DM normoalbuminuric controls ( Haplotype distribution. Three-locus AGT haplotype analysis, stratified by study subjects is shown in table 4. Of the eight AGT haplotypes identified, select haplotypes were positively or negatively associated with DN. These comprised -6A/174T/235M (ATM) and -6A/174M/235M (AMM), which were lower, and -6G/174T/235M (GTM), -6A/174T/235T (ATT), -6G/174M/235T (GMT), and -6A/174M/235T (AMT) haplotypes, which were found at higher frequencies among DN patients compared to normoalbuminuria control subjects, thus conferring disease protective and susceptibility and nature to these haplotypes, respectively. Of the haplotypes identified, only -6G/174T/ 235T (GTT) was significantly different between microalbuminuric and macroalbuminuric patients.
Regression analysis. The association of AGT polymorphic variants with DN was examined first at the univariate and then at the multivariate level. Multivariate analysis confirmed the association of select haplotypes with microalbuminuria and macroalbuminuria, after adjustment for the covariates: total cholesterol, LDL and triglyceride levels (table 5) . Taking the AGT -6A/174T/235M (ATM) haplotype as reference (OR 1.00), univariate analysis identified the GTM (p < 0.001), ATT (p < 0.001), GMT (p < 0.001) and AMT (p < 0.001) haplotypes to be positively associated, and AMM (p < 0.001) to be negatively associated with microalbuminuria (table 5) . Of these, GTM (p = 0.006) and ATT (p = 0.004) were positively associated, and AMM (p = 0.027) was associated with decreased odds of macroalbuminuria. However, the frequencies of the identified AGT haplotypes were not significantly different between microalbuminuria and macroalbuminuria T2DM patients, thereby demonstrating that AGT haplotypes are of value in predicting DN development rather than DN severity (table 6) .
Discussion
In addition to its well-documented role in the regulation of sodium homeostasis, extracellular fluid volume and blood pressure, 10, 11 increasing evidence suggests a contribution from the RAAS to DN pathogenesis. Specific RAAS gene variants were identified as risk factors for T2DM complications, including CHD, 22 nephropathy 15,22,30 and retinopathy. 31 Other studies yielded contradictory findings regarding the contribution of AGT gene variants to the risk of T2DM complications, 25, 26, [32] [33] [34] and an ethnic contribution of AGT effects appears likely. This case-control study of 405 normoalbuminuric, 329 microalbuminuric and 183 macroalbuminuric Tunisian T2DM patients demonstrated significant association of M235T and A-6G variants with DN, but not with DN severity, as the allelic or genotypic distribution was comparable between the two DN groups. This is the first report of the association between the three AGT polymorphic variants and DN in the ethnically homogeneous (North African) Tunisian population, and the first to identify specific DN-susceptible and DN-protective haplotypes in T2DM patients. The gender distribution, mean age, and hypertension status were comparable between the three groups included in our study. Although not reaching statistical significance, lower BMI (p = 0.052) and waist-to-hip ratio (p = 0.172) was seen in the macroalbuminuric vs. normoalbuminuric patients. Although not addressed here, it is tempting to speculate that this may be a direct consequence of the strict dietary management of macroalbuminuric patients in our centres. Whereas the age at T2DM onset was comparable between the three groups, T2DM duration was significantly different between DN (microalbuminuric and macroalbuminuric patients) and normoalbuminuric patients, consistent with previous findings that longer T2DM duration increases the risk of DN development. 1, 35 In addition, increased frequency of DR was noted in DN cases, which was more pronounced in macroalbuminuric patients, thus strengthening the notion that the nephropathy was the result of diabetes, more so than unrelated causes. Significantly higher HbA1c, 6, 36 and elevated total cholesterol and triglyceride levels, 35, 36 were associated with increased renal injury, in agreement with previous reports on DN development. Neither LDL nor HDL was different between the three groups, and this was attributed to comparable BMI and the absence of morbid obesity in the groups analysed. 37 Given the role of renin in blood pressure regulation and development of DN, 38 and as renin gene variants were associated with increased risk of vascular complications, 39, 40 we evaluated the contribution of the renin -4063C/T promoter variant to the risk for DN. In our hands, there was no association of renin -4063T allele or -4063C/T genotypes with DN. Although this was not surprising, as it has not yet been demonstrated for any population, 41 a larger study from different ethnic groups will be need to confirm, or alternatively rule out any contribution of renin -4063C/T polymorphism to T2DM complications, including DN.
AGT 235T/T and -6G/G genotypes, and 235T and -6G alleles were associated with increased DN risk. Logistic regression analysis confirmed the association of both variants with DN, in agreement with previous studies documenting the association of M235T variant with DN, 22, 30, 31, 42 and with increased UAE and retinopathy. 31, 42 The association of M235T with DN appeared to be independent of its effect on hypertension (data not shown), consistent with a recent US study. 22 Our findings were in disagreement with other studies on Caucasian, 26, 27, [32] [33] [34] and non-Caucasian 30 populations regarding the relationship between M235T and DN. This may be reconciled by difference in patient selection, 26, 27, 30, 32 sample size, 26, 27, 32 or ethnic/racial background, 26, 27, 30, [32] [33] [34] exemplified by higher prevalence of the AGT 235 T-allele and the AGT (-6) G-allele in Japanese compared with Caucasian populations. 28 In contrast to our previous 15 and current findings, a recent small study on Tunisian T2DM patients (39 hypertensive and 22 normotensive T2DM patients) claimed no association of M235T (and ACE I/D variant) with increased risk of T2DM complications. 25 As that study was severely underpowered, this questions the validity of the conclusions reached. A limited number of studies investigated the association between AGT T174M variant and T2DM complications, but with inconsistent findings. 34, 43, 44 In our hands, AGT 174M/M genotype, and 174M allele were not associated with an increased risk of DN, irrespective of the extent of DN (micro-and macroalbuminuria). This was in agreement with some, 32, 34, 44 but not all 27, 30 studies, which on the contrary suggested that AGT T174M variant was linked with increased risk of DN. These differences may be reconciled by difference in patient selection (ESRD vs. normotensive T2DM patients), 30 selection of controls, 27, 43 ethnic/racial background 27, 30 and to the relatively lower sample size employed in these studies. 27, 30 Insofar as proteinuria in adults is a multi-factorial condition frequently linked with diabetes, especially in advanced chronic kidney disease, the issue of whether proteinuria is due to diabetes or some other aetiology remains debatable. Although the possibility of an ongoing state of chronic kidney disease not related to diabetes contributing to the development of proteinuria in our patients remains to be seen, and as renal biopsies are not routinely done in our centres for the confirmation of DN, it appears unlikely that the proteinuria was the result of T2DM-unrelated causes. This was substantiated by the finding that all DN patients were normoalbuminuric at initial diagnosis, and positive proteinuria was confirmed years after the initial diagnosis.
By demonstrating a statistically significant association of M235T and G-6A, but not renin -4063C/T or AGT T174M variants with increased risk for nephropathy among Tunisian T2DM patients, this study extends earlier studies linking polymorphisms of RAAS genes with DN development. The strengths of this study lie in the sample size used (917 T2DM patients), which was sufficiently powered to reduce type I errors. Although it may be argued that chance findings, as opposed to ethnic differences or contribution of confounding variables, may explain the inconsistency between our findings and those of others, the adoption of regression analysis and identification of DN-susceptible and protective AGT haplotype rules out or minimises this possibility. However, our study has some limitations, namely that it was limited to a specific ethnic group (North African Tunisian Arabs), which coupled with the potential linkage of the AGT variants investigated with other AGT or nearby gene variants, necessitates large population-based replication studies on different ethnic groups.
